Purixan
Purixan (mercaptopurine) is an antineoplastic antimetabolite (purine antagonist) formulated as an oral suspension (20 mg/mL). It is designed to provide accurate and consistent dosing for pediatric and adult patients undergoing maintenance therapy for acute lymphoblastic leukemia (ALL).
Dosage by Body Weight
The standard starting dose of Purixan is 1.5 to 2.5 mg/kg (or 50 to 75 mg/m² of body surface area) taken orally once daily. Doses must be individualized based on clinical response, hematological tolerance, and genetic factors such as TPMT or NUDT15 deficiency. It should be taken on an empty stomach, either 1 hour before or 2 hours after food or milk.
- Body Weight
- Below 5 kg
- Dose
- Individualized weight-based calculation required (approx. 1.5 - 2.5 mg/kg daily)
- Frequency
- Once daily
- Tracking Notes
- Must be calculated and prescribed by a pediatric oncologist based on body surface area (BSA) or exact body weight.
- Body Weight
- 5-7 kg
- Dose
- 7.5 mg to 17.5 mg (0.38 mL to 0.88 mL)
- Frequency
- Once daily
- Tracking Notes
- Calculated based on standard starting range of 1.5 to 2.5 mg/kg/day. Monitor CBC weekly.
- Body Weight
- 8-10 kg
- Dose
- 12 mg to 25 mg (0.60 mL to 1.25 mL)
- Frequency
- Once daily
- Tracking Notes
- Adjust doses based on hematological response. Avoid administering with milk or dairy products.
- Body Weight
- 11-15 kg
- Dose
- 16.5 mg to 37.5 mg (0.83 mL to 1.88 mL)
- Frequency
- Once daily
- Tracking Notes
- Shake bottle vigorously for at least 30 seconds before administration. Use the provided oral dosing syringe.
- Body Weight
- 16-20 kg
- Dose
- 24 mg to 50 mg (1.20 mL to 2.50 mL)
- Frequency
- Once daily
- Tracking Notes
- Requires regular monitoring for myelosuppression, hepatotoxicity, and dose adjustments in patients with TPMT deficiency.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Individualized weight-based calculation required (approx. 1.5 - 2.5 mg/kg daily) | Once daily | Must be calculated and prescribed by a pediatric oncologist based on body surface area (BSA) or exact body weight. |
| 5-7 kg | 7.5 mg to 17.5 mg (0.38 mL to 0.88 mL) | Once daily | Calculated based on standard starting range of 1.5 to 2.5 mg/kg/day. Monitor CBC weekly. |
| 8-10 kg | 12 mg to 25 mg (0.60 mL to 1.25 mL) | Once daily | Adjust doses based on hematological response. Avoid administering with milk or dairy products. |
| 11-15 kg | 16.5 mg to 37.5 mg (0.83 mL to 1.88 mL) | Once daily | Shake bottle vigorously for at least 30 seconds before administration. Use the provided oral dosing syringe. |
| 16-20 kg | 24 mg to 50 mg (1.20 mL to 2.50 mL) | Once daily | Requires regular monitoring for myelosuppression, hepatotoxicity, and dose adjustments in patients with TPMT deficiency. |
Formulation
Purpose
Maintenance therapy for acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen.
Generic Name
MercaptopurineScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.